Skip to main content
. 2020 Jul 9;21(14):4852. doi: 10.3390/ijms21144852

Table 2.

WNT/β -catenin pathway inhibitors in melanoma (preclinical study).

Compound Target
Mode of Action
Research Model References
C59 porcupine inhibitor (synergizes with CTLA4-targeting antibodies in mouse melanoma models) WM266 human melanoma cell line; B16/F10 mouse melanoma cell line; patient derived Hu-175, Hu-422, Hu-424, Hu-451 human melanoma cell lines [176]
WNT-2Ab WNT2 antibody LOX, FEMX melanoma cell lines; [177]
FJ9 DVL inhibitor LOX melanoma cell line [178]
G007-LK tankyrase
inhibitor
(sensitizes melanoma to PD-1 immune checkpoint blockade)
B16/F10 mouse melanoma cell line [179]
fisetin (i) GSK3-β
inhibitor
B16F10 mouse melanoma cell line [180]
(ii) activator of GSK3-β, DKK1 and WIF-1; FZD and LRP5/6 inhibitor 451Lu human melanoma cells; athymic (nu/nu) female nude mice [181]
lupeol blocking the translocation of β-catenin to the nucleus Mel 928, Mel 1241 and Mel 1011 human melanoma cell lines [182]
pentoxifylline β-catenin DMBC11, 12, 17, 19, 21 patient-derived melanoma
cell lines
[183]
PKF115-584 β-catenin SKMEL28, A375, BLM, SKMEL19 and 451Lu human melanoma cell lines [100]